Remove Drug Pricing Remove Immunization Remove Pharmaceutical Manufacturing
article thumbnail

Preliminary Injunction Decision in Chambers of Commerce Case Provides First Insights Into Merits of Medicare Negotiations Cases

FDA Law Blog: Biosimilars

By Faraz Siddiqui — Last week, a federal court in Ohio denied a preliminary injunction motion by four Chambers of Commerce in their lawsuit against the Medicare Drug Price Negotiation Program. Standing The Defendants questioned, and the court reviewed, Plaintiffs’ standing. Order at 24.

article thumbnail

January 2025 Newsletter

Safe Biologics

This expansion continues a flawed policy that threatens innovation and jeopardizes patient access to critical treatments, including drugs vital for cancer treatment and popular new weight loss medications that have transformed the management of obesity and related conditions. What Will 2025 Mean for Medicare Drug Price Setting Under the IRA?